Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Consumer Products
GSK buys out Novartis in OTC venture
by Ryan Cross
April 2, 2018
| A version of this story appeared in
Volume 96, Issue 14
GlaxoSmithKline will spend $13 billion to buy Novartis’s 36.5% stake in the two drug companies’ consumer health care venture. GSK will fully own a business that includes Sensodyne toothpaste and over-the-counter pills. Vasant Narasimhan, Novartis’s new CEO, says the sale will help fuel his firm’s strategy of buying smaller pharmaceutical companies. The news came less than a week after GSK and Reckitt Benckiser both dropped out of the bidding for Pfizer’s consumer health care business, which Pfizer hopes to sell for $20 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter